Model-based adjusted odds ratio of predictors for aromatase inhibitor adherence measured by medication possession ratio (MPR) > = 80% among Medicare and Medicaid dual eligible beneficiaries diagnosed with hormone receptor-positive early stage breast cancer from 2007 to mid-2009. This evidence concerns the gene NR4A1 and breast carcinoma.